We assign a technical rating of 2 out of 10 to BRNS. BRNS's overall performance in the market is below average. Also recent evolutions are not that positive. Both the medium and short term picture give negative signs.
The long term trend is still negative, but the short term trend is neutral. It is advised to wait a little bit longer to see how this turns out.
When comparing the yearly performance of all stocks, BRNS is a bad performer in the overall market: 86% of all stocks are doing better.
BRNS is currently trading in the lower part of its 52 week range, which is not a good signal. Agreed, the S&P500 Index is also not doing fantastic, but it still sitting in the middle of its 52 week range.
Warning: BRNS has an average volume of 24989 traded shares per day. This is quite low and it might be dangerous to invest in illiquid stocks.
In the last month BRNS has a been trading in the 0.64 - 1.06 range, which is quite wide. It is currently trading near the high of this range.
Volume is considerably higher in the last couple of days, which is what you like to see during a strong movement up.
BRNS is an average performer in the Biotechnology industry, it outperforms 53% of 566 stocks in the same industry.
Prices have been rising strongly lately, it may be a good idea to wait for a consolidation or pullback before considering an entry.